12:00 AM
 | 
Oct 08, 2012
 |  BC Week In Review  |  Company News  |  Deals

Katama Pharmaceuticals, Sanochemia deal

Sanochemia granted newco Katama exclusive rights in North America to develop and commercialize spasticity product tolperisone. Katama will initially develop the small molecule muscle relaxant for...

Read the full 107 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >